These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 3607760

  • 1. Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model.
    Pazdur R, Redman BG, Corbett T, Phillips M, Baker LH.
    Cancer Res; 1987 Aug 01; 47(15):4213-7. PubMed ID: 3607760
    [Abstract] [Full Text] [Related]

  • 2. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
    Brown TD, Ettinger DS, Donehower RC.
    J Clin Oncol; 1986 Aug 01; 4(8):1270-6. PubMed ID: 3525770
    [Abstract] [Full Text] [Related]

  • 3. Spiromustine: a new agent entering clinical trials.
    Shoemaker DD, O'Dwyer PJ, Marsoni S, Plowman J, Davignon JP, Davis RD.
    Invest New Drugs; 1983 Aug 01; 1(4):303-8. PubMed ID: 6381379
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
    Rasschaert M, Schrijvers D, Van den Brande J, Dyck J, Bosmans J, Merkle K, Vermorken JB.
    Anticancer Drugs; 2007 Jun 01; 18(5):587-95. PubMed ID: 17414628
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, Heeger S, Kränzle M, Edler L, Frei E, Fiebig HH, Heene DL, Maier-Borst W, Queisser W.
    Clin Cancer Res; 1999 Apr 01; 5(4):753-9. PubMed ID: 10213209
    [Abstract] [Full Text] [Related]

  • 6. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B, Takimoto CH, Goetz A, Diab S, Hammond LA, Smetzer L, Schwartz G, Gazak R, Callaghan JT, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 2003 Nov 15; 9(15):5540-9. PubMed ID: 14654534
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
    Marshall JL, Wellstein A, Rae J, DeLap RJ, Phipps K, Hanfelt J, Yunmbam MK, Sun JX, Duchin KL, Hawkins MJ.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2347-54. PubMed ID: 9815633
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ, Wiegand RA, LoRusso PM, Baker LH.
    Clin Cancer Res; 1995 Aug 15; 1(8):831-7. PubMed ID: 9816052
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ.
    Clin Cancer Res; 2002 Aug 15; 8(8):2524-9. PubMed ID: 12171879
    [Abstract] [Full Text] [Related]

  • 10. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
    LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L.
    Clin Cancer Res; 1995 Dec 15; 1(12):1487-93. PubMed ID: 9815948
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC, McElroy EA, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM.
    Clin Cancer Res; 1999 Mar 15; 5(3):525-31. PubMed ID: 10100703
    [Abstract] [Full Text] [Related]

  • 13. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M, Jeha S, O'Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H.
    Clin Cancer Res; 1997 Dec 15; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [Abstract] [Full Text] [Related]

  • 14. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS, Mangalik A, Ferguson J, Elias L.
    Clin Cancer Res; 1995 Jun 15; 1(6):615-20. PubMed ID: 9816023
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ, Budman DR, Young RR, Kreis W, Ingram R, Schulman P, Cherny RC, Wright J, Behr J, Snow C, Schacter LP.
    Bone Marrow Transplant; 1996 Nov 15; 18(5):851-6. PubMed ID: 8932836
    [Abstract] [Full Text] [Related]

  • 16. Phase I clinical trial of mitozolomide.
    Newlands ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MF.
    Cancer Treat Rep; 1985 Nov 15; 69(7-8):801-5. PubMed ID: 4016790
    [Abstract] [Full Text] [Related]

  • 17. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
    Mirsalis JC, Schindler-Horvat J, Hill JR, Green CE, Mitoma C, Tomaszewski JE, Tyson CA, Donohue SJ.
    Cancer Chemother Pharmacol; 2003 Mar 15; 51(3):193-201. PubMed ID: 12655436
    [Abstract] [Full Text] [Related]

  • 18. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Weiss GR, Isaacs RE, Margolin KA, Fisher RI, Ernest ML, Mier J, Oleksowicz L, Eckhardt JR, Levitt D, Doroshow JH.
    Clin Cancer Res; 1997 Jan 15; 3(1):39-46. PubMed ID: 9815535
    [Abstract] [Full Text] [Related]

  • 19. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS, Abbruzzese JL, Bogaard K, Lassere Y, Fukushima M, Mita A, Kuwata K, Hoff PM.
    Cancer; 2006 Sep 15; 107(6):1383-90. PubMed ID: 16902987
    [Abstract] [Full Text] [Related]

  • 20. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
    Hidalgo M, Rodriguez G, Kuhn JG, Brown T, Weiss G, MacGovren JP, Von Hoff DD, Rowinsky EK.
    Clin Cancer Res; 1998 Nov 15; 4(11):2763-70. PubMed ID: 9829740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.